TY - JOUR
T1 - Determination of intrinsic creatine transporter (SLC6A8) activity and creatine transport function of leukocytes in rats
AU - Taii, Ayaka
AU - Tachikawa, Masanori
AU - Ohta, Yusuke
AU - Hosoya, Kenichi I.
AU - Terasaki, Tetsuya
N1 - Funding Information:
Acknowledgments We thank Ms. A. Niitomi for secretarial assistance and Drs. S. Akanuma and Y. Uchida for fruitful discussions. This study was supported in part by the Japan Agency for Medical Research and Development (AMED)
Publisher Copyright:
© 2020 The Pharmaceutical Society of Japan
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Creatine transporter (CRT) deficiency (CRT-D) results in a significant reduction of brain creatine levels, which causes various neurological symptoms in early childhood, and diagnosis of the severity of CRT-D based on the residual CRT transport activity in liquid biopsy samples would be beneficial for early intervention. The apparent reduction in creatine transport activity in CRT-D is thought to be due to reduced intrinsic CRT-mediated creatine transport per CRT protein and/or reduced absolute CRT protein expression on the plasma membranes. The purpose of this study was thus to determine the normal level of intrinsic CRT-mediated creatine transport activity based on absolute CRT protein quantification using rat CRT-overexpressing HEK293 cells (CRT/HEK293 cells), and to clarify creatine transport in erythrocyte- and leukocyte-enriched fractions isolated from the circulating blood of rats. The intrinsic creatine transport rate was calculated to be 0.237µL/(min·fmol CRT) based on the initial uptake rate and the absolute CRT protein level in CRT/ HEK293 cells. Taking into account Avogadro’s constant, the creatine transport activity per CRT protein is estimated to be 1190 creatine/(min·CRT molecule) in the presence of [14C]creatine at an extracellular concentration of 5µM. Isolated leukocyte-enriched fraction exhibited mRNA expression of CRT and partially Na+dependent [14C]creatine transport, whereas erythrocytes showed neither. These characteristics suggest that the leukocytes contain the CRT-mediated creatine uptake system, and are available for evaluation of residual CRT transport activity in CRT-D patients.
AB - Creatine transporter (CRT) deficiency (CRT-D) results in a significant reduction of brain creatine levels, which causes various neurological symptoms in early childhood, and diagnosis of the severity of CRT-D based on the residual CRT transport activity in liquid biopsy samples would be beneficial for early intervention. The apparent reduction in creatine transport activity in CRT-D is thought to be due to reduced intrinsic CRT-mediated creatine transport per CRT protein and/or reduced absolute CRT protein expression on the plasma membranes. The purpose of this study was thus to determine the normal level of intrinsic CRT-mediated creatine transport activity based on absolute CRT protein quantification using rat CRT-overexpressing HEK293 cells (CRT/HEK293 cells), and to clarify creatine transport in erythrocyte- and leukocyte-enriched fractions isolated from the circulating blood of rats. The intrinsic creatine transport rate was calculated to be 0.237µL/(min·fmol CRT) based on the initial uptake rate and the absolute CRT protein level in CRT/ HEK293 cells. Taking into account Avogadro’s constant, the creatine transport activity per CRT protein is estimated to be 1190 creatine/(min·CRT molecule) in the presence of [14C]creatine at an extracellular concentration of 5µM. Isolated leukocyte-enriched fraction exhibited mRNA expression of CRT and partially Na+dependent [14C]creatine transport, whereas erythrocytes showed neither. These characteristics suggest that the leukocytes contain the CRT-mediated creatine uptake system, and are available for evaluation of residual CRT transport activity in CRT-D patients.
KW - Creatine transporter
KW - Creatine transporter deficiency
KW - Diagnosis
KW - Intrinsic transport activity
KW - Leukocyte
KW - Quantitative targeted absolute proteomics
UR - http://www.scopus.com/inward/record.url?scp=85080840455&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85080840455&partnerID=8YFLogxK
U2 - 10.1248/bpb.b19-00807
DO - 10.1248/bpb.b19-00807
M3 - Article
C2 - 32115505
AN - SCOPUS:85080840455
SN - 0918-6158
VL - 43
SP - 474
EP - 479
JO - Biological and Pharmaceutical Bulletin
JF - Biological and Pharmaceutical Bulletin
IS - 3
ER -